CPT

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida

Retrieved on: 
Wednesday, April 3, 2024
Johns Hopkins Hospital, MLSS, Anesthesia, Risk, Trauma, MD, ESI, CPT, ASC, Injection, Safety, Spine, Pain management, Pain, Physician, Epidural steroid injection, Nursing

ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida. PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers. PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.

Key Points: 
  • ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.
  • PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers.
  • PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.
  • Adoption of the technology follows a successful evaluation by Dr. Sanjay Bakshi, MD, a pain management physician and CEO of PRC Alliance Pain Relief Centers in Ormond Beach, Florida.

Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023

Retrieved on: 
Monday, April 1, 2024
Growth, MLSS, Webcast, Telephone, Education, Dental Service Organizations, Operating cost, Hospital, United, CPT, Injection, Pain management, STA, Physician

Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.

Key Points: 
  • Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.
  • For the year ended December 31, 2023, international revenue was approximately $4.1 million, a decrease of $724,000 compared to December 31, 2022.
  • Gross profit for the year ended December 31, 2023, was $6.8 million versus $4.9 million for the year ended December 31, 2022.
  • Operating loss for the year ended December 31, 2023, was $7.1 million versus $8.8 million for the year ended December 31, 2022.

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Friday, March 29, 2024
Patient, PTCL, G&A, IND, Prednisone, Neoplasm, Therapy, SMDC, Medicinal chemistry, Lymphoma, Research, Frontiers Media, RNA polymerase II, Body modification, Primate, RNA, NIH, CPT, Potential, Safety, CDK9, ADC, MCL1, Solubility, Oncogene, RNA polymerase, Venetoclax, Journal, Manuscript, Cancer, Peripheral T-cell lymphoma, AACR, Antibody, MYC, Downregulation and upregulation, DLBCL, Annual general meeting, HER2, European Hematology Association, EHA, Spacecraft, PDX, Bangladesh Technical Education Board, Journal of Medicinal Chemistry, Blood, Pharmaceutical industry

PALO ALTO, Calif., March 29, 2024 (GLOBE NEWSWIRE) --  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Vincerx presented preclinical data at the 2023 AACR Annual Meeting demonstrating significant activity in patient-derived xenograft (PDX) lymphoma mouse models.
  • Vincerx shared preclinical data at the 2023 ASH Annual Meeting showing superior activity and safety compared with commercially available B-cell targeted ADCs.
  • For the fourth quarter and full year 2023, Vincerx reported a net loss of $4.9 million, or $0.23 per share, and a net loss of $40.2 million, or $1.89 per share, respectively.
  • For the fourth quarter and full year 2022, Vincerx reported a net loss of $13.8 million, or $0.65 per share, and a net loss of $63.0 million, or $3.00 per share, respectively.

TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters

Retrieved on: 
Monday, March 25, 2024
LTD, Y90, Patient, PLLC, Hospital, Research, Cancer, Telehealth, Radiopharmaceutical, Life expectancy, CPT, Liver cancer, ISO, Physician, Health

TeleDaaS is launching a pilot program and enrolling early adopters.

Key Points: 
  • TeleDaaS is launching a pilot program and enrolling early adopters.
  • By eliminating inefficient workflows, TeleDaaS saves time for physicians and helps hospitals improve their revenue capture under existing CPT codes.
  • "With this new service, we are elevating healthcare by providing dosimetry services directly to hospitals,” said TeleDaaS Chief Medical Officer Dr. Mark Crockett, M.D.
  • TeleDaaS is designed to provide highly-scalable, best-in-class dosimetry services that integrate with existing imaging workflows, to transform cancer treatment research and development and treatment planning.

Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, March 12, 2024
Patient, G&A, BioCryst Pharmaceuticals, Eye, Drug delivery, Clinical trial, AAO, Extension, Webcast, Pharming, CPT, Safety, Disease, SPA, American Academy of Ophthalmology, Compass, Insurance, Diabetic retinopathy, Conference call, Aura, AMD, TKI, CLS, FDA, Administration, Conference, SCS, DME, American Academy, OASIS, Injection, Research and development, Axitinib, Pharmaceutical industry

ALPHARETTA, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • License Revenue: License and other revenue for the fourth quarter of 2023 was $6.3 million, compared to $0.3 million for the fourth quarter of 2022.
  • Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2023 were $6.3 million, compared to $5.0 million for the fourth quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2023 were $2.9 million, compared to $3.2 million for the fourth quarter of 2022.
  • Other Expense: Non-cash interest expense for the fourth quarter of 2023 was $2.3 million, compared to $2.0 million for the fourth quarter of 2022.

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Surgery, Health Technology, Health Insurance, Biotechnology, Managed Care, General Health, Pharmaceutical, Health, Optical, Retina, IOP, HCPCS, Glaucoma, Ocular hypertension, OAG, OHT, Patient, Corporation, APC, Eye, Surgeon, CPT, Travoprost, GKOS, OPPS, Idose, Medicare, CMS, Government, Intraocular pressure

The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.

Key Points: 
  • The new J-code for iDose TR, J7355, is set to become effective July 1, 2024.
  • It is expected to increase patient access in the U.S. and has been published here on the CMS website.
  • “The receipt of a product-specific J-code for iDose TR supports our market access initiatives to enable broad access and coverage for patients suffering from open-angle glaucoma or ocular hypertension,” said Thomas Burns, Glaukos chairman and chief executive officer.
  • iDose TR is intended to improve the standard of care by addressing the ubiquitous patient non-compliance issues and chronic side effects associated with topical glaucoma medications.

Octave Bioscience Accelerates Leadership in Precision Care for Neurodegenerative Diseases with Addition of World-Class Commercial Executives

Retrieved on: 
Thursday, March 28, 2024
Neurology, Biotechnology, General Health, Health, Artificial Intelligence, Medical Devices, Technology, Other Health, Growth, Multiple sclerosis, Physician, Patient, COE, Biomarker, AI, Jeron, CPT, Drug development, Pharmaceutical industry

Octave recently appointed CEO Doug Biehn, who brings over 20 years of healthcare experience building and scaling growth businesses.

Key Points: 
  • Octave recently appointed CEO Doug Biehn, who brings over 20 years of healthcare experience building and scaling growth businesses.
  • Additionally, Octave recently expanded its precision care platform beyond multiple sclerosis into Parkinson’s with a $10 million grant from The Michael J.
  • Prior to joining Octave, Jeron built and scaled world-class commercial teams resulting in new standards of care and three successful acquisitions.
  • "Joining Octave means getting the chance to make a real difference in the lives of patients with neurodegenerative diseases,” said Debbie Ledet.

With Cedar Pay, Talkiatry Takes the Stress Out of Paying for Mental Healthcare

Retrieved on: 
Tuesday, April 2, 2024
Partnership, Patient, Public, Patient satisfaction, CPT, Apple Pay, Anxiety, Health, CFO, Health insurance

NEW YORK, April 2, 2024 /PRNewswire/ -- Talkiatry, a leading provider of high-quality, in-network psychiatric care, is now offering simple and transparent online payment solutions through its partnership with Cedar, an end-to-end healthcare financial engagement platform. As one of the largest employers of psychiatrists in the United States, Talkiatry now streamlines payments for thousands of patients every month.

Key Points: 
  • As one of the largest employers of psychiatrists in the United States, Talkiatry now streamlines payments for thousands of patients every month.
  • One in five U.S. adults are affected by mental illness each year and poor mental health is seen as a top threat to public health .
  • Focused on ensuring a caring and human-centered approach at every step of treatment, Talkiatry saw an opportunity to improve the patient's financial experience in mental healthcare by engaging with Cedar.
  • Nearly 50% of consumers say their well-being or healing has been negatively impacted by difficulty paying a healthcare bill," said Florian Otto, CEO and Co-founder of Cedar.

BlueWind Medical Revi™ Implantable Tibial Neuromodulation Device Now Available to Patients in Texas

Retrieved on: 
Thursday, March 21, 2024
De novo, American Medical Association, Urinary bladder, Renaissance, Patient, Ankle, Quality of life, Surgeon, CPT, Urinary incontinence, Commercial software, Urology, Medicare, Neuromodulation, USD, FDA, CMS, Health, Food

PARK CITY, Utah, March 21, 2024 /PRNewswire/ -- BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Urologists Dr. Henry Ruiz and Dr. Natalia Hernandez at the Urology Institute at Renaissance are the first providers of Revi in the state of Texas.

Key Points: 
  • "Urge Incontinence, although a common condition with profound impacts on quality of life, has long been under-diagnosed and under-treated.
  • With the advent of Revi, we now have a safe and proven patient-centric solution that can be tailored and optimized to meet the needs of patients," stated Dr. Ruiz.
  • In October 2023, the American Medical Association (AMA) CPT Editorial Panel announced the final Current Procedural Terminology (CPT) code to describe the subfascial tibial neuromodulation implant procedure, 0817T.
  • We consider it a privilege to contribute to improving the quality of life for the millions living with urge incontinence," stated Dan Lemaitre, Chief Executive Officer of BlueWind Medical.

Pediatric Associates and Ambience Healthcare Partner to Redefine Pediatric Care with Generative AI

Retrieved on: 
Tuesday, March 19, 2024
Attention, Documentation, ECW, Environment, CDI, Partnership, Patient, Electronic health record, Child, AI, United, ICD-10, CPT, Pediatrics, EHR, Parent, Health, Nursing

Pediatric Associates is the largest private pediatric primary care group in the United States.

Key Points: 
  • Pediatric Associates is the largest private pediatric primary care group in the United States.
  • "By deploying AI, Pediatric Associates is providing our clinicians with the most advanced technology available to allow them to focus on patients and families instead of administrative work.
  • Our team at Pediatric Associates worked closely with Ambience to co-create the single best AI solution for pediatrics, which seamlessly integrates into eCW.
  • As Pediatric Associates continues to expand operations and offer world class pediatric care, Ambience will also support easy onboarding with eCW, by simplifying workflows and reducing time spent in the EHR.